+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D



Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D



American Journal of Kidney Diseases 64(5): 770-780



Information is limited regarding utilization patterns and costs for chronic kidney disease-mineral and bone disorder (CKD-MBD) medications in Medicare Part D-enrolled dialysis patients. Retrospective cohort study. Annual cohorts of dialysis patients, 2007-2010. Cohort year, low-income subsidy status, and dialysis provider. Utilization and costs of prescription phosphate binders, oral and intravenous vitamin D analogues, and cinacalcet. Using logistic regression, we calculated adjusted odds of medication use for low-income subsidy versus non-low-income subsidy patients and for patients from various dialysis organizations, and we report per-member-per-month and average out-of-pocket costs. Phosphate binders (∼83%) and intravenous vitamin D (77.5%-79.3%) were the most commonly used CKD-MBD medications in 2007 through 2010. The adjusted odds of prescription phosphate-binder, intravenous vitamin D, and cinacalcet use were significantly higher for low-income subsidy than for non-low-income subsidy patients. Total Part D versus CKD-MBD Part D medication costs increased 22% versus 36% from 2007 to 2010. For Part D-enrolled dialysis patients, CKD-MBD medications represented ∼50% of overall net Part D costs in 2010. Inability to describe utilization and costs of calcium carbonate, an over-the-counter agent not covered under Medicare Part D; inability to reliably identify prescriptions filled through a non-Part D reimbursement or payment mechanism; findings may not apply to dialysis patients without Medicare Part D benefits or with Medicare Advantage plans, or to pediatric dialysis patients; could identify only prescription drugs dispensed in the outpatient setting; inability to adjust for MBD laboratory values. Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056824045

Download citation: RISBibTeXText

PMID: 24833203

DOI: 10.1053/j.ajkd.2014.04.014


Related references

Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D. American Journal of Kidney Diseases 59(5): 670-681, 2012

Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Services Research 48(4): 1311-1333, 2013

Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications. Journal of Oncology Practice 13(2): E152-E162, 2017

Thienopyridine use after coronary stenting in low income patients enrolled in Medicare part D receiving maintenance dialysis. Journal of the American Heart Association 4(4): -, 2015

The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey. Clinical Therapeutics 28(1): 140-145, 2006

Medicare Part D's effects on elderly patients' drug costs and utilization. American Journal of Managed Care 14(11 Suppl): Sp14-Sp22, 2008

Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study. Bmc Nephrology 13: 140, 2013

Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs. Ophthalmology 125(3): 332-339, 2017

Mineral and bone disorder in Chinese dialysis patients: a multicenter study. Bmc Nephrology 13: 116, 2013

Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes. Cancer 122(10): 1598-1607, 2017

Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine 2018, 2018

CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). CKD-MBD in CKD patients not yet on dialysis; Status Quo. Clinical Calcium 20(7): 1004-1010, 2010

The effect of the Medicare Part D benzodiazepine exclusion on the utilization patterns of benzodiazepines and substitute medications. Research in Social and Administrative Pharmacy 10(2): 438-447, 2014

County-level access to opioid use disorder medications in medicare Part D (2010-2015). Health Services Research 2019, 2019

The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort study. Bmc Nephrology 17(1): 199, 2017